Abstracts Archive - Page 860 of 2607 - ACR Meeting Abstracts

Abstract Number: 0354 • ACR Convergence 2020
How Do TNF-alpha-Inhibitors in Medical History Affect Patient Reported Outcomes and Retention in Ankylosing Spondylitis Patients Treated with Secukinumab in Real World? – German Observational Study
Uta Kiltz¹, Jan Brandt-Jürgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ³Ambulantes Rheumazentrum, Erfurt, Germany, ⁴Hannover Medical School, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody that selectively inhibits interleukin 17A, is approved for treatment of patients with ankylosing spondylitis (AS). However, there…
Abstract Number: 0355 • ACR Convergence 2020
Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial
Georg Schett¹, Matthew J. Loza², Arumugam Palanichamy², Oliver FitzGerald³, Christopher Ritchlin⁴, Frédéric Baribaud⁵ and Kristen Sweet⁵, ¹Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ²Janssen Research & Development, LLC, Spring House, ³Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁴Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁵Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Guselkumab (GUS), an interleukin-23p19-subunit monoclonal antibody, demonstrated efficacy compared to placebo (PBO) in reducing skin and musculoskeletal signs and symptoms in patients with active…
Abstract Number: 0356 • ACR Convergence 2020
Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity
Laure Gossec¹, Philip Mease², Alice Gottlieb³, Deepak Assudani⁴, Jason Coarse⁵, Barbara Ink⁶ and Laura Coates⁷, ¹Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Raleigh, NC, ⁶UCB Pharma, Slough, ⁷University of Oxford, Oxford, United Kingdom
Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes and…
Abstract Number: 0357 • ACR Convergence 2020
Suppressing Inflammation Rather Than Lowering the Disease Activity Score Should Be Targeted During TNF Inhibitor Treatment to Slow Radiographic Changes in Patients with Ankylosing Spondylitis
Bon San Koo¹, Ji Seon Oh², Seo Young Park³, Ji Hui Shin⁴, Bora Nam⁴, Seunghun Lee⁴, Kyung Bin Joo⁴ and Tae-Hwan Kim⁴, ¹Inje University Seoul Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea, ²Asan Medical Center, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ³Asan Medical Center, University of Ulsan College of Medicine, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁴Hanyang University Hospital for Rheumatic Diseases, Seoul, Seoul-t'ukpyolsi, Republic of Korea
Background/Purpose: Treatment with tumor necrosis factor (TNF) inhibitors has the effect of slowing radiographic progression by improving symptoms and reducing inflammation in patients with ankylosing…
Abstract Number: 0358 • ACR Convergence 2020
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Ankylosing Spondylitis? – Real World Data from German Observational Study
Elke Riechers¹, Uta Kiltz², Jan Brandt-Jürgens³, Peter Kästner⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ⁴Ambulantes Rheumazentrum, Erfurt, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: There is growing body of evidence that smoking is associated with more active and severe disease in patients (pts) with ankylosing spondylitis (AS)1,2. The…
Abstract Number: 0359 • ACR Convergence 2020
Clinical Characteristics of Psoriatic Arthritis Patients with Physician-Identified Spondylitis, According to HLA-B27 Status: An Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip Mease¹, Soumya Chakravarty², Robert McLean³, Taylor Blachley³, Toana Kawashima⁴, Iris Lin⁵, Jonathan Uy⁶, Arthur Kavanaugh⁷ and Alexis Ogdie⁸, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ³Corrona, LLC, Waltham, MA, ⁴Corrona, LLC, Waltham, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, ⁶Janssen Scientific Affairs, LLC, Horsham, ⁷UC San Diego Health System, San Diego, CA, ⁸Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Axial disease in psoriatic arthritis (PsA) has been reported to occur in anywhere from 25% to 75% of PsA patients (pts). It can be…
Abstract Number: 0360 • ACR Convergence 2020
Does Smoking Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from German Observational Study
Elke Riechers¹, Uta Kiltz², Jan Brandt-Jürgens³, Peter Kästner⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, ⁴Ambulantes Rheumazentrum, Erfurt, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Several studies have shown an negative association between smoking status and psoriatic arthritis (PsA) clinical outcomes1,2. The German non-interventional study AQUILA provides real-world data…
Abstract Number: 0361 • ACR Convergence 2020
Response to Treatment with Ixekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis Based on HLA-B27 Status and Disease Duration
Victoria Navarro-Compán¹, Jose Maldonado-Cocco², Proton Rahman³, Andris Kronbergs⁴, David Sandoval⁴, So Young Park⁴, Theresa Hunter⁴ and Marina Magrey⁵, ¹Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ²University of Buenos Aires School of Medicine, Buenos Aires, Argentina, ³Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁴Eli Lilly and Company, Indianapolis, ⁵Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: In this analysis, we evaluate the efficacy of ixekizumab at week 16 in patients with non-radiographic axial spondyloarthritis (nr-axSpA) with or without baseline HLA-B27…
Abstract Number: 0362 • ACR Convergence 2020
Patients with Psoriatic Arthritis Treated with Guselkumab Achieved Psoriasis-Related Symptom-Free State and Had No Skin Condition Impact on Their Health Related Quality of Life
Jan Dutz¹, Joseph Merola², Chenglong Han³, Alexa Kollmeier⁴, Bei Zhou³, Prasheen Agarwal³, Ya-Wen Yang⁵, May Shawi⁶ and Atul Deodhar⁷, ¹Vancouver General Hospital, Vancouver, Canada, ²Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC, La Jolla, CA, ⁵Janssen Global Services, LLC, Malvern/Horsham, PA, ⁶Janssen Global Services, LLC, Toronto, ON, Canada, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: Guselkumab (GUS), a monoclonal antibody that specifically binds to the p19 subunit of IL-23, is approved for psoriasis. In the DISCOVER-2 Phase 3 trial…
Abstract Number: 0363 • ACR Convergence 2020
Efficacy of Ixekizumab on Disease Activity and Quality of Life in Patients with Active Nonradiographic Axial Spondyloarthritis and Objective Signs of Inflammation, Stratified by Baseline CRP/Sacroiliac Joint MRI Status
Walter Maksymowych¹, Helena Marzo-Ortega², Mikkel Ǿstergaard³, Lianne Gensler⁴, Joerg Ermann⁵, Atul Deodhar⁶, Denis Poddubnyy⁷, David Sandoval⁸, Rebecca Bolce⁸, Andris Kronbergs⁸, Soyi Liu-Leage⁹, Gabriel Doridot⁸, Vladimir Geneus⁸, Ann Leung¹⁰, David Adams⁹ and Martin Rudwaleit¹¹, ¹University of Alberta, Edmonton, AB, Canada, ²The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ³University of Copenhagen, Copenhagen, Denmark, ⁴University of California San Francisco, San Francisco, CA, ⁵Brigham and Women’s Hospital, Boston, ⁶Oregon Health & Science University, Portland, OR, ⁷Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁸Eli Lilly and Company, Indianapolis, ⁹Eli Lilly and Company, Indianapolis, IN, ¹⁰Syneos Health, Morrisville, ¹¹Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany
Background/Purpose: Ixekizumab (IXE), a high-affinity anti-interleukin-17A monoclonal antibody, is effective in patients (pts) with active non-radiographic axial spondyloarthritis (nr-axSpA), who had elevated C-reactive protein (CRP)…
Abstract Number: 0364 • ACR Convergence 2020
Subcutaneous Secukinumab 150 Mg Provides Sustained Relief in Total and Nocturnal Back Pain, Morning Stiffness, Fatigue, and Low Disease Activity in Patients with Active Ankylosing Spondylitis: End-of-study (5-year) Data from the MEASURE 2 Trial
Helena Marzo-Ortega¹, Corinne Miceli-Richard², Sonja Gill³, Marina Magrey⁴, Paula Machado⁵, Abhijit Shete⁶, Jianyuan Wang⁶, Susanne Rohrer⁶ and Atul Deodhar⁷, ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ²Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ³412 – 3075 Hospital Gate, Oakville, Canada, ⁴Case Western Reserve University School of Medicine, Cleveland, OH, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: Patients (pts) with ankylosing spondylitis (AS) report pain (70–80%), stiffness (20–40%), and fatigue (50–60%) as the most troubling symptoms. Early diagnosis and sustained improvement…
Abstract Number: 0365 • ACR Convergence 2020
Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN)
Colin Edgerton¹, Andrew Frick², Simon Helfgott³, Kent Kwas Huston⁴, Jasvinder Singh⁵ and Nehad Soloman⁶, ¹Articularis Healthcare, Summerville, SC, ²Trio Health, Louisville, CO, ³BWH- HMS, Boston, MA, ⁴Kansas City Physician Partners, Kansas City, MO, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ
Background/Purpose: Apremilast is the one targeted immune modulating (TIM) treatment for psoriatic arthritis (PsA) that may be combined with csDMARDs, biologic therapies, or used as…
Abstract Number: 0366 • ACR Convergence 2020
Symptoms of Peripheral Arthritis Are Significantly Improved in Patients with Ankylosing Spondylitis Treated with Secukinumab
Philip Mease¹, Atul Deodhar², Renato Calheiros³, Xiangyi Meng⁴, Todd Fox⁵ and Xenofon Baraliakos⁶, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Novartis Pharmaceuticals Corporation, Hoboken, NJ, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Aesch, Switzerland, ⁶Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton associated with pain, stiffness, and disability.1 Up to 66% of patients (pts)…
Abstract Number: 0367 • ACR Convergence 2020
Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (DISCOVER-1 and DISCOVER-2)
Stefan Siebert¹, Iain McInnes², Matthew J. Loza³, Keying Ma⁴, Karen Leander⁴, Vani Lakshminarayanan⁴, Carol Franks⁴, Philip Cooper⁴ and Kristen Sweet⁴, ¹University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Janssen Research & Development, LLC, Spring House, ⁴Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Guselkumab (GUS), an IL-23 inhibitor monoclonal antibody (MAb) that specifically binds the IL-23p19 subunit, demonstrated efficacy compared to placebo (PBO) in reducing skin &…
Abstract Number: 0368 • ACR Convergence 2020
Comparable Impact and Burden of Disease of Psoriatic Arthritis Patients with Limited Joint Involvement vs. Those with More Extensive Joint Involvement: Interim Results from a Prospective, Multicenter, Real-World Study in Patients Treated with Apremilast
Tim Jansen¹, Arie van Vliet² and Marijn Vis³, ¹Viecuri MC, Venlo, Netherlands, ²Amgen B.V., Breda, Netherlands, ³Erasmus UMC, Rotterdam, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is associated with a high burden of disease and an increased risk of comorbidities. Recent data suggest that patients with moderate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].